Findlay Park Partners LLP boosted its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 20.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,032,151 shares of the medical research company’s stock after buying an additional 350,000 shares during the period. Thermo Fisher Scientific makes up about 3.3% of Findlay Park Partners LLP’s portfolio, making the stock its 7th largest position. Findlay Park Partners LLP owned about 0.52% of Thermo Fisher Scientific worth $312,138,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Independent Portfolio Consultants Inc. increased its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer increased its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the last quarter. Penserra Capital Management LLC increased its position in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after buying an additional 100 shares during the last quarter. South Texas Money Management Ltd. purchased a new position in Thermo Fisher Scientific during the first quarter valued at about $202,000. Finally, Cedar Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 3.7% in the first quarter. Cedar Wealth Management LLC now owns 1,473 shares of the medical research company’s stock valued at $226,000 after buying an additional 53 shares in the last quarter. 87.60% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Inc (NYSE:TMO) traded down 0.19% during mid-day trading on Friday, reaching $172.57. 1,182,702 shares of the company’s stock were exchanged. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The firm’s 50-day moving average is $176.71 and its 200 day moving average is $166.56. The stock has a market capitalization of $67.32 billion, a PE ratio of 30.06 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $2.03 EPS. Analysts forecast that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.35%. Thermo Fisher Scientific’s payout ratio is 10.45%.

ILLEGAL ACTIVITY WARNING: “Findlay Park Partners LLP Buys 350,000 Shares of Thermo Fisher Scientific Inc (NYSE:TMO)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/19/thermo-fisher-scientific-inc-nysetmo-shares-bought-by-findlay-park-partners-llp-updated-updated-updated.html.

Several equities research analysts have weighed in on the company. Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Barclays PLC reaffirmed an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Wells Fargo & Company reissued an “outperform” rating and set a $200.00 target price (up from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. Finally, Citigroup Inc. reissued a “buy” rating and set a $201.00 target price (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $188.56.

In other news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel P. Shine sold 4,688 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total transaction of $805,773.44. Following the completion of the transaction, the insider now directly owns 29,200 shares in the company, valued at approximately $5,018,896. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,506 shares of company stock worth $6,834,758. 0.49% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.